Neurological disorders Archives

sleep homeostasis sandman channel oxford cncb

News and Trends 8 Aug 2016

The Brain’s Sleep Switch was just discovered, zZz …

Researchers from the University of Oxford have discovered how certain neurons control when we go to sleep. The biology behind it involves an ion channel that reacts to the ‘happy chemical’ dopamine, changing places in the neurons. Sleep is essential to health, with the Center for Disease Control even calling insufficient sleep a public health […]

August 8, 2016 - 3 minutesmins - By Denise Neves Gameiro

galvani bioelectronics electroceuticals gsk verily google

News and Trends 2 Aug 2016

Google and GSK invest €630M to create a new Bioelectronics Champion

GSK and Verily Life Sciences are creating a new company together, Galvani Bioelectronics. Along with €630M in investment, it’ll inherit intellectual property to pioneer a new class of therapies – bioelectronic medicines. GSK is one of the big Pharma based in Europe and has had a strong presence in many hype fields of medical Biotech. Examples are […]

August 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

taurx tau protein tangles biotech alzheimers

News and Trends 28 Jul 2016

World first Drug to ‘dissolve’ Tau-tangles in Alzheimer’s has Phase III Results

The much-anticipated results of TauRx’s Phase III trial for Alzheimer’s disease have finally been disclosed. Despite some complicated effects, this could be the first available working therapy for Alzheimer’s patients. According to the WHO, Alzheimer’s disease is the cause of up to 70% of dementia cases, which translates to over 30 million patients worldwide. As the world population ages, Alzheimer’s […]

July 28, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 22 Jul 2016

Oryzon develops Epigenetic Therapies against Cancer and Alzheimer’s

This week we’re exchanging a very warm and welcoming country for another. We are heading to Barcelona, the wonderful capital of Catalunya in Spain, to visit Oryzon, our Biotech of The Week and maybe (just maybe) have a little swim in the Barceloneta beach. City: Barcelona (Spain) Founded: 2000 Employees: 35 Financial Data: €81.50M Market Cap (Bolsa de […]

July 22, 2016 - 2 minutesmins - By Joachim Eeckhout

News and Trends 14 Jul 2016

Sci-fi Spinal Cord Implant could help Paralyzed Patients walk again

Getting up from a wheelchair is a shared dream of paralyzed people all across the world. A dream that might soon become true thanks to a new skin-like implant that directly stimulates the patients’ spinal cord through electric pulses. The sci-fi technology developed by researchers at École Polytechnique Fédérale of Lausanne (EPFL) in Switzerland has […]

July 14, 2016 - 2 minutesmins - By Lourdes Riquelme

pharnext marie tooth disease IPO pharnext

News and Trends 14 Jul 2016

French Biotech that makes Drugs faster and cheaper IPO’s for €31M

Pharnext has successfully completed its IPO on the Euronext Paris exchange, allowing it to move forward with Phase II and III trials for Neurological diseases that include Alzheimer’s. Based in Paris, Pharnext is developing new therapies for neurological conditions, including rare diseases such as Charcot-Marie-Tooth Disease. New partners to join this biotech in the €31M IPO include Galapagos […]

July 14, 2016 - 2 minutesmins - By Dani Bancroft

multiple sclerosis zinbryta daclizumab biogen abbvie

News and Trends 6 Jul 2016

Newly Approved therapy reduces frequency of Multiple Sclerosis relapses by 54%

Biogen and AbbVie have been granted EU marketing authorization for Zinbryta (daclizumab), to treat adult patients with relapsing forms of multiple sclerosis. Relapse frequency per year was shown to be reduced by up to 45% against other treatments, and 54% against placebo. Biogen is trying to emphasise the need for choice of treatments for MS, as the […]

July 6, 2016 - 3 minutesmins - By Dani Bancroft

affiris peptide vaccine affitope cholesterol

News and Trends 29 Jun 2016

Vienna-based Biotech raises €10M to fight Metabolic diseases and Parkinson’s

AFFiRiS has received €10M from previous investors and one additional backer, adding up to €130M in total funding (half from grants and licensing incomes). This money fuels a pipeline in cardiometabolic and neurodegenerative diseases as more candidates break into clinical development. Based at the Campus Vienna Biocenter (Austria), AFFiRiS is developing immunotherapies to prevent chronic diseases. […]

June 29, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 23 Jun 2016

Alzheimer’s closer to a Vaccine with new Slovakian Phase II Trial

Axon Neuroscience is starting a Phase II trial with its immunotherapy for Alzheimer’s disease, which redirects the immune system against defective Tau proteins, thought to be the main cause of this major disease. Alzheimer’s disease is the cause of up to 70% of dementia cases, according to WHO, which translates in over 30 million patients […]

June 23, 2016 - 2 minutesmins - By Denise Neves Gameiro

kings college depression biomarker diagnostic

News and Trends 14 Jun 2016

New Biomarkers could make Personalized Medicine for Depression

Researchers from King’s College London have succeeded in developing a blood test that can help choose the best treatment for depression patients – a big improvement over the current trial-and-error approach. Depression doesn’t seem to be a particularly popular indication for biotechs, unlike other nervous systems diseases that reached significant milestones in the last year. Moreover, one […]

June 14, 2016 - 3 minutesmins - By Denise Neves Gameiro

huntingtons rochester copenhagen glia transplant

News and Trends 9 Jun 2016

Brain Cell Transplant could help with incurable Neurodegenerative Disease

Researchers from Copenhagen and the US have succeeded in slowing the progression of Huntington’s disease in mice with a transplant of healthy human brain cells. This provides a new route to tackle this incurable fatal disease. Cell therapies are promising for some of the most serious diseases, from their role in cancer treatment (one of the […]

June 9, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 17 May 2016

New Italian Drug is FDA approved for trials in Rare Neurological Disease

Newron sees its Investigational New Drug application approved by the FDA. It can now begin clinical trials for Rett Syndrome patients – a rare neurological disorder. Based near Milan (Italy), Newron is a Biopharma developing therapies for diseases of the central nervous system (CNS). Last year it raised over €23M to advance its pipeline, which features candidates […]

May 17, 2016 - 2 minutesmins - By Denise Neves Gameiro

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us